secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aura Biosciences, Inc. (AURA)
CIK:        0001501796
Form:       8-K
Filed at:   2021-11-24T23:59:59+00:00
Accession:  0000950170-21-004906
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aura Biosciences Q3 net loss $8.8M; AU-011 data and IPO highlight quarter
-------------------------------------------------------------------------

- Net loss $8.8M for Q3 2021 vs $3.6M YoY; R&D expenses $6.4M (up from $2.9M).
- Cash $81.8M at Sep 30; IPO raised $86.9M gross in Nov 2021 at $14.00/share.
- Final Phase 1b/2 data: 64% tumor control, 71% visual acuity preservation for AU-011 in choroidal melanoma.
- Plans to start AU-011 pivotal program H2 2022; Phase 1a in NMIBC expected H2 2022.
- Added Antony Mattessich to board and Chris Primiano as CBO in September 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501796/000095017021004906/0000950170-21-004906-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501796/000095017021004906/aura-20211124.htm
  HTML page:      https://secwatch.observer/filing/0000950170-21-004906

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer